Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Vials Over Sterility Concerns Apothecary Pharma has issued a recall of compounded tirzepatide and NAD+ (nicotinamide adenine dinucleotide) injectable vials due to sterility concerns, according to a report from Managed Healthcare Executive.
Read Full ArticleAll News
North Carolina Compounder Recalls Tirzepatide Vials…
North Carolina Compounder Recalls Tirzepatide Vials Amid Ongoing Scrutiny of Compounded GLP-1 Products A compounding pharmacy based in North Carolina has issued a recall of tirzepatide vials, according to a report circulated via Google News and aggregated by inkl.
Twenty AGs Issue Letter on Chinese-Sourced Ingredients in Some Compounded GLP-1s and Peptides
Twenty State Attorneys General Raise Alarms Over Chinese-Sourced Ingredients in Compounded GLP-1 Drugs A coalition of twenty state attorneys general has issued a letter addressing concerns about Chinese-sourced active pharmaceutical ingredients (APIs) used in some compounded versions of GLP-1 recep...
Eli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know
Eli Lilly's Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know Eli Lilly and Company has expanded its legal campaign against unauthorized sales of its investigational weight-loss and metabolic drug retatrutide, filing lawsuits that legal analysts say cou...
Henry Meds Lawsuit (Updated September 2026)
Henry Meds Faces Continued Legal Scrutiny Amid Broader Compounded Peptide Crackdown Henry Meds, one of the more prominent telehealth platforms selling compounded GLP-1 medications such as semaglutide and tirzepatide, remains the subject of ongoing litigation tracking, according to an updated report...
Compounded GLP-1 Crisis: What Patients and Policymakers Need to Know
Overview of the Regulatory Action The compounded GLP-1 receptor agonist controversy represents one of the most consequential pharmaceutical compliance disputes of the past decade, implicating drug shortage law, compounding pharmacy oversight, and consumer safety enforcement simultaneously.
Empower Pharmacy Lawsuit: Updated Sept 2026 Claims
Empower Pharmacy Faces Updated Legal Claims as Litigation Continues Into September 2026 Empower Pharmacy, one of the nation's largest compounding pharmacies and a major supplier of compounded semaglutide, tirzepatide, and other peptide-based therapies, is again in the legal spotlight following repo...
RFK Says 14 Banned Peptides Are Coming Back Legal. GHK-Cu Is One of Them, But There's a Catch Nobody's Talking About
RFK Jr. Signals Return of 14 Banned Peptides, But Regulatory Fine Print Raises Questions Health and Human Services Secretary Robert F. Kennedy Jr.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly Files Suit Against Six Firms Over Unauthorized Retatrutide Sales Eli Lilly and Company has filed lawsuits against six companies it accuses of illegally manufacturing, marketing, and selling retatrutide, an experimental obesity and metabolic drug that has not yet received approval from the...
Qatar's Health Ministry bans trading, use or promotion of unlicensed peptide products
Qatar Health Ministry Cracks Down on Unlicensed Peptide Products Qatar's Ministry of Public Health has issued a ban on the trading, use, and promotion of unlicensed peptide products, according to a report from The Peninsula Qatar.
What would it take to get peptides on the shelf?
What Would It Take to Get Peptides on the Shelf? NPR Report Spotlights Regulatory Crossroads for Booming Industry A recent NPR report poses a deceptively simple question that has become one of the most consequential regulatory puzzles in American health and wellness: what would it actually take to ...
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug Retatrutide, an experimental weight-loss and metabolic drug developed by Eli Lilly, is drawing intense attention from investors, physicians, and regulators alike, with some analysts projecting the broader obesity-drug market could event...
August 10, 2026: Compounded peptide injections recalled due to high endotoxin levels
Compounded Peptide Injections Recalled Over Endotoxin Contamination Concerns A recall of compounded peptide injection products has been issued after testing revealed elevated endotoxin levels, according to the Partnership for Safe Medicines, a nonprofit organization that tracks drug safety and coun...
Banned from sport over peptides: Kiwi world champion says he didn’t know he was doing anything wrong
New Zealand Athlete's Doping Ban Highlights Growing Peptide Regulatory Confusion A New Zealand world champion has been banned from competition after testing positive for banned peptides, telling reporters he was unaware he had done anything wrong, according to a report published by Stuff.
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
Eli Lilly Escalates Legal Fight Against Peptide Vendors Selling Unapproved Retatrutide Eli Lilly and Company has filed lawsuits against a number of pharmacies and peptide vendors accused of manufacturing, marketing, and selling retatrutide, the pharmaceutical giant's experimental triple-hormone rec...
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
The 2026 GLP-1 Compounding Crackdown: What Pharmacists Need to Know Compounding pharmacies that have built substantial business lines around semaglutide and tirzepatide are bracing for intensified federal scrutiny as the calendar turns toward 2026, according to a report from Drug Topics titled "The...
One Year Later: Lessons in Compounding Compliance
Overview of the Regulatory Action The RealClearHealth commentary "One Year Later: Lessons in Compounding Compliance" arrives at a natural inflection point for the pharmacy compounding industry, marking roughly twelve months since the U.S.
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
This article is based on limited source information from a CBS News report referenced via Google News. Some contextual details reflect established public reporting on Eli Lilly's broader anti-counterfeiting and anti-diversion efforts regarding its weight-loss and diabetes drug portfolio.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide Eli Lilly and Company has filed lawsuits against six companies accused of illegally selling retatrutide, the pharmaceutical giant's experimental triple-agonist obesity drug that has not yet received approva...
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide
Eli Lilly Targets Gray-Market Sellers of Experimental Weight-Loss Drug Eli Lilly and Company has filed six separate lawsuits aimed at shutting down what the pharmaceutical giant describes as a burgeoning "black market" for retatrutide, an experimental triple-hormone receptor agonist still undergoin...
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Eli Lilly Moves to Shut Down Alleged Black Market Sales of Experimental GLP-1 Drug Eli Lilly and Company has taken action against alleged black market sales of one of its experimental GLP-1 receptor agonist drugs, according to a report from The Hill.